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Circulating angiopoietin-like 
8 (ANGPTL8) is a marker of 
liver steatosis and is negatively 
regulated by Prader-Willi Syndrome
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Massimo Scacchi1 & Paolo Marzullo1,4
ANGPTL8 is a liver-derived protein related to insulin-sensitivity. Its relationship with obesity and 
liver function in Prader-Willi syndrome (PWS) is unknown. The present study investigated circulating 
ANGPTL8 in PWS and controls with common obesity, assessing its association to liver steatosis. 
For this purpose, 20 obese PWS and 20 controls matched for body mass index (BMI), sex and age 
underwent analysis of ANGPTL8 levels, glucose and lipid metabolism. Liver function tests and degree 
of liver steatosis by ultrasonography (US), fat-free mass (FFM) and fat mass (FM) by dual-energy 
x-ray absorptiometry (DEXA) were also assessed. In comparison to controls, obese PWS showed 
lower values of FFM (p < 0.0001) and higher FM (p = 0.01), while harbouring higher HDL cholesterol, 
lower triglycerides and OGTT-derived insulin levels, as well as a lower prevalence and severity of liver 
steatosis. With respect to obese controls, ANGPTL8 levels were significantly lower in PWS (p = 0.007) 
and overall correlated with transaminase levels and the severity of liver steatosis, as well as FFM 
(p < 0.05 for all). By a stepwise multivariable regression analysis, ANGPTL8 levels were independently 
predicted by PWS status (p = 0.01) and liver steatosis (p < 0.05). In conclusion, ANGPTL8 levels are 
lower in PWS than obese controls and are inversely associated with the severity of liver steatosis. 
Further studies should investigate the potential genetic basis for this observation.
Prader-Willi syndrome (PWS) is an imprinted neurobehavioral condition caused by the lack of expression of 
genes located on the paternal chromosome 15q11.2-q13. There are three main genetic subtypes in PWS: pater-
nal 15q11-q13 deletion (65–75% of cases), maternal uniparental disomy of chromosome 15 (UPD15) (20–30% 
of cases), and imprinting defects (1–3%)1. The smallest deletions discovered to date demonstrate that the 
SNORD116 snoRNA gene cluster can explain much of the PWS phenotype2. Clinically, PWS is characterized by 
neonatal hypotonia and failure to thrive, cognitive and behavioural disorders, endocrine defects such as short 
stature and hypogonadism, autonomic dysregulation. PWS is tipically associated with a lack of satiety, which 
generates obsessive craving for food and results in extreme obesity by the adult age3.
Adult patients with PWS show peculiar body and metabolic features. Compared to BMI-matched controls, 
PWS patients harbour a predominant accumulation of subcutaneous adipose tissue, with lower accumulation of 
visceral adipose tissue than that observed in patients with common obesity4–6. In addition, lean body mass and 
muscle function is impaired7, and results in reduced resting energy expenditure (REE) and decreased voluntary 
activity8. Despite this unfavourable body composition, the metabolic phenotype of PWS is characterized by lower 
insulin levels and higher insulin sensitivity as opposed to obese controls9, 10, while dyslipidaemia rarely occurs in 
PWS11. Although the molecular mechanisms driving this peculiar metabolic profile are not well understood, it 
can be hypothesized that the elevation of orexigenic hormones, such as ghrelin12, 13, and different expression of 
adipocytokines14, particularly adiponectin15, could intervene to regulate the metabolic profile of PWS adults16.
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A recently identified liver protein, angiopoietin-like 8 (ANGPTL8), has been described to be involved in 
different metabolic pathways related to glucose and lipid metabolism17–19. As summarized by Tseng et al., sev-
eral researchers have investigated the subcellular localization of ANGPTL8, demonstrating that its cytoplasmic 
vesicle-like distribution is likely involved in the lipid regulation pathway17. Serum ANGPTL8 has been detected 
in sera from humans and mice, with its levels found to be positively correlated with triglycerides (TG) and very 
low-density lipoprotein (VLDL) levels18. Intracellular ANGPTL8 is associated with lipid droplets, suggesting that 
ANGPTL8 may serve as a lipoprotein and could be secreted or taken up with a lipid-associated compartment18.
Regarding its function/s in glucose homeostasis, ANGPTL8 might be key in regulating postprandial glucose 
metabolism. In fact, liver ANGPTL8 over-expression in mice increases insulin-mediated synthesis of glycogen19. 
Moreover, it is able to promote the suppression of key enzymes involved in gluconeogenic pathways, thereby 
improving insulin resistance19.
To date, the metabolic significance of ANGPTL8 in human obesity and obese patients with PWS is unknown. 
As such, this study was designed to investigate the relationship between ANGPTL8 levels and adiposity, metabolic 
homeostasis and liver steatosis in association with obesity and the PWS condition.
Methods
Patients. This study enrolled 40 patients, consisting of 20 PWS adults with obesity (10 F/10 M; age, 
34.2 ± 7.6 years; BMI, 45.5 ± 9.4 kg/m2) and 20 BMI-matched control subjects (10 F/10 M; age, 35.0 ± 8.3 years; 
BMI, 48.6 ± 10.2 kg/m2), referred to our institution for work-up and rehabilitation of obesity and its comor-
bidities. All PWS individuals received a diagnosis based on typical syndromic features confirmed by molecular 
genetic studies of chromosome 15, including 15q11-q13 deletion in 16 (10 males and 6 females) and UPD15 
in the remaining 4 females. Exclusion criteria included any liver disease except for newly diagnosed steatosis, 
kidney failure, autoimmune diseases, uncontrolled hypothyroidism and/or diabetes mellitus, exposure to glu-
cocorticoids or alcohol consumption. With respect to hormone replacement therapy in PWS, 9 patients were 
treated with rhGH, 2 female patients with estrogens and 2 patients with levothyroxine. Four PWS patients were 
treated with psychotropic medications. The experimental procedure was approved by the ad hoc Ethical Research 
Committee of the Istituto Auxologico Italiano, Verbania, Italy. A written informed consent was obtained from the 
PWS patients and their parents or guardians, and from the obese participants. The study protocol conformed to 
the guidelines of the European Convention on Human Rights and Biomedicine concerning biomedical research.
Body measurements and instrumental tests. All subjects underwent body measurements wearing 
light underwear, in fasting conditions after voiding. Weight and height were measured to the nearest 0.1 kg and 
0.1 cm, respectively, using standard methods. BMI was expressed as body mass (kg)/height (m)2. Obesity was 
defined for any BMI over 30 kg/m2 20. Waist circumference (WC) was measured midway between the lowest rib 
and the top of the iliac crest after gentle expiration; hip measurements were taken at the greatest circumference 
around the nates.
A dual-energy x-ray absorptiometry (DEXA; GE Lunar, Madison, WI, USA) was performed for the assess-
ment of body mass. This was expressed as lean body mass in kilograms and fat body mass as the percentage of 
total body mass.
The REE was expressed in kilocalories/24 h and determined in a thermoregulated room (22–24 °C) by com-
puted open-circuit indirect calorimetry, measuring resting oxygen uptake and resting carbon dioxide production 
by a ventilated canopy (Sensormedics, Milan, Italy) at 1-min intervals for 30 min, expressed as 24 h value.
In order to assess the presence and severity of liver steatosis, liver US was performed by the same operator who 
was blinded to the laboratory and clinical data at the time of the procedure, using a high-resolution US system 
(LOGIQ 7, GE Healthcare, Waukesha, WI, USA). The degree of hepatic steatosis was assessed semi-quantitatively 
on the basis of hepatorenal echo contrast, liver brightness, deep attenuation and vascular blurring. Liver steatosis 
was established by a validated method of US grading (categorized as: G0 = absent; G1 = mild; G2 = moderate, 
G3 = severe steatosis)21, to accomplish for the subjective difficulties of PWS patients to undergo invasive or radi-
ological assessment (MRI) where patients’ collaboration was needed.
Laboratory tests. Blood samples were drawn under fasting conditions, centrifuged, and stored at −80 °C 
until required.
Serum ANGPTL8 levels were assessed using a commercially available human EIA kit (Phoenix Pharmaceutics, 
Inc, Burlingame, CA, USA). The assay procedure was performed in accordance with the manufacturer’s instruc-
tions. All samples were analyzed in duplicate. Intra-assay CV and inter-assay CV of ANGPTL8 were less than 10% 
and 15% respectively. Minimum detectable concentration was 0.12 ng/mL. Furthermore, the EIA was specific for 
human ANGPTL8. In addition, quality controls were included in all EIA measurements with the results within 
the expected range.
Routine laboratory data included levels of C-reactive protein, alkaline phosphatase, aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), glucose, total cholesterol, 
high-density (HDL) and low-density lipoprotein (LDL) cholesterol, triglycerides (TG) and glycated haemoglobin 
(HbA1c), measured by enzymatic methods (Roche Diagnostics, Mannheim, Germany). Levels of insulin were 
measured using a Cobas Integra 800 Autoanalyzer (Roche Diagnostics, Indianapolis, IN, USA). Ultrasensitive 
C-reactive protein (CRP) was measured by CRP (latex) HS Roche kit.
Glucose homeostasis was evaluated by oral glucose tolerance test (OGTT) in all subjects and glucose toler-
ance was expressed, according to ADA recommendations22, as normal fasting plasma glucose (FPG) if <100 mg/
dl (5.6 mmol/l); impaired FPG (IFG) if FPG was 100–125 mg/dl (6.9 mmol/l); impaired glucose tolerance 
(IGT) if 2-h post-OGTT plasma glucose was 140–199 mg/dl (7.8–11.0 mmol/l); T2DM if FPG was ≥126 mg/
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dl (≥7 mmol/l) two days apart, or if 2-h post-OGTT plasma glucose was ≥200 mg/dl (≥11.1 mmol/l). HbA1c 
values of 5.7 and 6.5% were considered as the threshold of normal glucose metabolism and T2DM, respectively.
Matsuda23, 24 and Stumvoll25 indexes were used to measure insulin sensitivity obtained from plasma glucose 
and insulin concentrations during the oral glucose tolerance test (OGTT). The Matsuda index provides a reasona-
ble index of whole-body insulin sensitivity23, 24 and was calculated using the following formula: 10,000/square root 
of [(fasting glucose × fasting insulin) × (glucose × insulin at time 120 min during OGTT)]. The Stumvoll index is 
a predictor of individual’s insulin sensitivity and β-cell function25 and was calculated using the following formula: 
0.156 − (0.0000459 × insulin at time 120 min during OGTT) − (0.000321 × fasting insulin) − (0.00541 × glucose 
at time 120 min during OGTT).
Insulin resistance was calculated by the homeostatic model of insulin resistance (HOMA-IR) index: insu-
lin (mIU/L) × [glucose (mmol/L)/22.5]26. A HOMA-IR value greater than 2.0 was considered indicative of 
insulin resistance, as obtained in a sample of the Italian population27. The homeostatic model of β cell function 
(HOMA-B) was used to describe the functionality of pancreatic beta cells and calculated using the following 
formula: 20 × [insulin (mIU/L)/glucose (mmol/L) − 3.5]26.
Data analysis. Statistical analysis was performed using SPSS version 18 (Somers, NY, USA). Values are 
expressed as means ± standard deviation (SD). For comparative analysis, ANOVA between the 2 groups and 
paired-T test intra-groups were used. For comparative analysis of ANGPTL8 levels across liver steatosis catego-
ries, Kruskall-Wallis test with Dunn’s correction was used. Pearson’s correlation analysis and the Chi square were 
used to identify significant associations between variables of interest. Stepwise multivariate regression analysis 
was used to evaluate the independent association of variations in ANGPTL8 with metabolic, anthropometric or 
biochemical parameters. The multilinear model included PWS status (no PWS = 0; PWS = 1), liver steatosis or 
ALT levels, age, gender and BMI as independent variables. β coefficients and related significance values obtained 
from the models are reported. P < 0.05 was considered as statistically significant.
Results
A summary of anthropometric and biochemical data is reported in Tables 1 and 2, and Fig. 1. BMI values 
were comparable between the two groups and ranged, collectively, between 31.5–73.3 kg/m2. Severe obesity 
(BMI > 40 kg/m2) was present in 67.5% of cases (13 PWS and 14 obese patients). Abnormal glucose metabolism 
was detected in 50% of PWS and 55% of obese controls (T2DM in 25% of PWS and 20% of obese subjects, IGT in 
20% of PWS and 35% of obese controls, IFG in 5% of PWS and no controls).
Anthropometric parameters differed between groups. PWS showed lower values of REE (p < 0.0001) and 
FFM (p < 0.0001), and higher %FM (p = 0.01) with respect to obese controls. Nevertheless, in the PWS group 
we observed lower OGTT-derived insulin (p = 0.02), higher HDL (p = 0.02 for all) and lower TG (p = 0.01) and 
urate levels (p = 0.004), which was suggestive of a better metabolic profile in PWS compared to obese controls.
Liver function tests and liver steatosis evaluated by US resulted less impaired in PWS than obese controls. 
In fact, transaminases levels were high (>40 U/L) in 3 PWS and in 7 obese patients (15% vs. 35%), while US 
documented liver steatosis in 14 PWS and 18 obese controls (70% vs. 90%; χ2 = 12.5, p < 0.001). According to 
the grading of liver steatosis, PWS had a higher prevalence of G0 (30% vs. 7%; χ2 = 17.5, p < 0.0001), a similar 
prevalence of G1 (20% vs. 20%, respectively) and G2 (30% vs. 33%, respectively), and a lower prevalence of G3 
score (20% vs. 40%; χ2 = 9.5, p < 0.01), when compared with obese controls.
Analysis of circulating ANGPTL8 showed overall significantly lower levels in PWS compared to obese con-
trols (Fig. 2). ANGPTL8 levels were only modestly overlapping between populations and were less variable in 
PWS than obese subjects. The greater dispersion around the mean of ANGPTL8 values in the obese group likely 
reflected differences in liver function, as confirmed by an elevation of AST and ALT levels in both outliers of the 
obese group of controls (Fig. 2). Corroborating these findings, correlation analysis in the two groups as a whole 
(Table 3) showed significant positive correlations between ANGPTL8 and AST (r = 0.35, p < 0.05), ALT (r = 0.38, 
p = 0.01), as well as with the grading of liver steatosis (r = 0.36, p < 0.05). These relationships were further sub-
stantiated by the observation of parallel increases of ANGPTL8 levels with the severity of liver steatosis (p = 0.01 
Variables PWS (n = 20) Obese (n = 20) P Value
Males/females 10/10 10/10 —
Age (years) 34.2 ± 7.6 35.0 ± 8.3 0.7
BMI (kg/m2) 45.5 ± 9.4 48.6 ± 10.2 0.3
Weight (Kg) 105.9 ± 23.5 137.6 ± 27.2 <0.001
Height (cm) 152.6 ± 8.1 168.5 ± 10.5 <0.0001
Waist (cm) 124.8 ± 15.2 132.6 ± 12.8 0.09
Hip (cm) 130.1 ± 16.8 140.4 ± 18.8 0.08
Waist-to-hip ratio 0.96 ± 0.08 0.95 ± 0.11 0.7
FM (%) 53.7 ± 6.1 47.5 ± 8.1 0.01
FFM (Kg) 47.8 ± 11.6 70.2 ± 13.7 <0.0001
REE (kcal/day) 1607.5 ± 281.3 2198.6 ± 402.1 <0.0001
Table 1. Summary of anthropometric data obtained in PWS subjects and obese controls. Data are expressed as 
mean ± SD. Comparison between populations was performed by ANOVA test. Significant differences are shown 
in bold characters. BMI, body mass index; FM, fat mass; FFM, fat free mass; REE, resting energy expenditure.
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by repeated measures ANOVA) (Fig. 3), and by association observed between ANGPTL8 levels and liver stea-
tosis in the group of obese controls (r = 0.53, p < 0.05). Of note, a significant association was also seen between 
ANGPTL8 levels and REE (r = 0.32, p = 0.05) as well as FFM (r = 0.31, p < 0.05), while only in PWS ANGPTL8 
levels were inversely associated with %FM (r = −0.46, p < 0.05). Significant correlations obtained on the entire 
dataset were lost after controlling for PWS status, thereby confirming the blunting effect of PWS on ANGPTL8 
levels (r = −0.42, p < 0.01). There were no differences in ANGPTL8 levels and liver steatosis when PWS group 
was analysed according to GH treatment or genotype (data not shown).
Stepwise multivariable regression analysis documented that ANGPTL8 levels were negatively predicted by 
PWS status (standardized β = −0.41, p = 0.01). After the removal of PWS status from the regression equation, 
ALT levels (standardized β = 0.39, p = 0.01) or the score of liver steatosis (standardized β = 0.35, p < 0.05), acted 
as independent predictors of ANGPTL8 levels.
Variables PWS (n = 20) Obese (n = 20)
P 
Value
ANGPTL8 (ng/mL) 0.58 ± 0.21 0.93 ± 0.50 0.007
Glucose OGTT0 (mg/dL) 100.6 ± 31.6 90.6 ± 10.0 0.1
Glucose OGTT120 (mg/dL) 125.1 ± 44.9 142.2 ± 47.8 0.3
Insulin OGTT0 (mIU/L) 10.7 ± 5.0 13.5 ± 6.2 0.1
Insulin OGTT120 (mIU/L) 53.4 ± 28.1 106.6 ± 86.5 0.02
C- Peptide (μg/L) 2.3 ± 0.9 3.2 ± 0.9 0.002
Matsuda 6.39 ± 6.37 3.51 ± 2.25 0.06
Stumvoll 0.077 ± 0.029 0.051 ± 0.045 0.05
HOMA-IR 2.6 ± 1.6 3.0 ± 1.5 0.4
HOMA-B 149.4 ± 57.0 194.9 ± 109.3 0.1
HbA1c (%) 5.8 ± 1.0 5.7 ± 0.5 0.5
AST (U/L) 18.9 ± 6.7 29.1 ± 15.1 0.01
ALT (U/L) 25.0 ± 16.9 40.5 ± 29.9 0.02
GGT (U/L) 36.9 ± 50.0 34.0 ± 26.6 0.8
ALP (U/L) 77.1 ± 19.6 73.7 ± 14.9 0.5
CHO (mg/dL) 178.6 ± 42.6 186.9 ± 25.2 0.4
LDL CHO (mg/dL) 118.9 ± 39.3 120.4 ± 21.9 0.8
HDL CHO (mg/dL) 48.9 ± 11.1 41.1 ± 9.2 0.02
TG (mg/dL) 97.3 ± 35.1 131.6 ± 45.1 0.01
Urate (mg/dL) 5.4 ± 1.0 6.5 ± 1.1 0.004
CRP (mg/dL) 1.2 ± 1.3 1.1 ± 0.7 0.7
Table 2. Summary of biochemical data obtained in PWS subjects and obese controls. Data are expressed as 
mean ± SD. Comparison between populations was performed by ANOVA test. Significance is shown in bold 
characters. OGTT, Oral Glucose Tolerance Test; OGTT0 and OGTT120, OGTT at time 0 min and 120 min; 
HOMA-IR, homeostatic model of insulin resistance; HOMA-B, homeostatic model of β cell function; HbA1c, 
glycated haemoglobin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma 
glutamyl transpeptidase; ALP, alkaline phosphatase; CHO, total cholesterol; LDL CHO, low density lipoprotein 
cholesterol; HDL CHO, high density lipoprotein cholesterol; TG, triglycerides; CRP, C-reactive protein.
Figure 1. OGTT-derived glucose levels (mg/dl) (A) and insulin levels (mIU/L) (B) obtained at time 0 min and 
120 min in PWS and controls. Intra-groups differences were assessed by paired T-test. Inter-group analyses were 
performed by ANOVA. For significance: *p < 0.0001 by paired T-test; §p = 0.02 by ANOVA.
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Figure 2. Individual values of circulating ANGPTL8 levels obtained in PWS patients and obese controls. Lines 
represent mean and standard deviation values in the two populations.
Parameters
ANGPTL8 levels
r p-value
Age (years) 0.04 0.7
Status −0.42 0.007
BMI (kg/m2) −0.04 0.7
FM (%) −0.26 0.1
FFM (kg) 0.31 0.04
REE (kcal/day) 0.32 0.05
Glucose OGTT0 (mg/dL) −0.10 0.5
Glucose OGTT120 (mg/dL) 0.30 0.08
Insulin OGTT0 (mIU/L) 0.09 0.5
Insulin OGTT120 (mIU/L) 0.30 0.08
C- Peptide (μg/L) 0.30 0.07
AST (U/L) 0.35 0.02
ALT (U/L) 0.38 0.01
Liver steatosis score 0.35 0.03
Table 3. Pearson’s correlation analysis between ANGPTL8 levels and anthropometric and biochemical 
parameters in the study populations as a whole. For obese status: PWS = 1, common obese = 0. Significance 
is shown in bold characters. BMI, body mass index; FM, fat mass; FFM, fat free mass; REE, resting energy 
expenditure; OGTT, Oral Glucose Tolerance Test; OGTT0 and OGTT120, OGTT at time 0 min and 120 min; 
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Figure 3. Histogram illustrating the prevalence (%) of liver steatosis in PWS and obese controls, and the 
corresponding ANGPTL8 levels across liver steatosis scores as obtained in the two population as a whole. 
Significance is expressed as obtained by ANOVA. Inter-group differences are listed in the Results section.
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Discussion
The present study analysed the association between ANGPTL8 levels and adiposity, metabolic profile and liver 
steatosis in relation to the adult PWS condition and obesity. Our results show that PWS patients harbor lower 
ANGPTL8 levels than obese controls and that ANGPTL8 levels are more closely associated with liver steatosis, 
than with body composition and metabolic homeostasis.
The metabolic phenotype of PWS is different as compared to common obesity and some metabolic complica-
tions typically related to obesity, such as insulin resistance and reduced hepatic insulin extraction, are less severe 
than expected for the degree of fat accumulation28. In addition, PWS is associated with peripheral rather than 
central distribution of body fat4, less severe metabolic signatures in adipocytes16, and abnormalities in growth 
hormone secretion, ghrelin levels and adipokine patterns, when compared to common obesity12, 14–16. From a 
clinical viewpoint, factors influencing these discrepancies are incompletely understood.
ANGPTL8 is a liver and adipose tissue-produced protein, involved in the regulation of triglyceride and glu-
cose metabolism. Its activity involves the ability of reducing serum triglyceride clearance and improving insulin 
resistance17, 29–33. In the current study, we observed lower circulating levels and less interindividual variability of 
ANGPTL8 in PWS when compared to subjects with common obesity. While insulin resistance and whole-body 
insulin sensitivity index did not greatly differ between PWS and obese controls, several anthropometric and meta-
bolic differences existed between the two populations. Particularly, PWS patients showed higher HDL cholesterol 
and lower TG levels than their control counterpart. Previous studies have suggested that PWS is characterized 
by a more efficient triglyceride storage likely due to an increase of adipose tissue lipoprotein lipase (LPL) activity, 
suggesting an altered pathway of fat mobilization and oxidation34. Noteworthy, ANGPTL8 shows the ability to 
suppress triglyceride clearance through the inhibition of LPL, thus increasing serum triglycerides33. Therefore, we 
speculate that the decreased serum ANGPTL8 levels in PWS could contribute in explaining the lower triglyceride 
levels seen in PWS when compared to obese controls. In our study groups, the role of circulating ANGPTL8 on 
glucose homeostasis and insulin resistance appeared to be of little relevance compared to data in the literature19. 
In fact, no correlations between ANGPTL8 and glucometabolic parameters were observed. These results do not 
disagree with recent data, but rather suggest that ANGPTL8 is not as robustly involved in β-cell proliferation as 
originally proposed35, at least in our study populations.
In the search for mechanisms to explain our observations, we noted that circulating ANGPTL8 paralleled 
the behaviour of crucial determinants of metabolic health, such as liver steatosis. In fact, circulating ANGPTL8 
levels were negatively associated with indices of liver steatosis, i.e. transaminases and US-derived scores of ste-
atosis, which are recognized non-invasive markers of liver impairment in obesity36–38. While liver biopsy is the 
gold-standard method for the accurate staging of non-alcoholic liver steatosis, several previous studies demon-
strated a strong correlation between US findings and the degree of liver steatosis documented by biopsy21, 39, 40. 
Bearing in mind the limitation of our approach, current data confirm that liver steatosis is less severe in PWS than 
in common obesity37, and substantiates the emerging role of liver steatosis on circulating ANGPTL8 in severe 
obesity, which is further strengthened by the results of correlation analyses and multivariable regression analyses. 
Being a primarily liver-produced protein, ANGPTL8 is positively associated with biochemical indices of liver 
injury and steatosis in overweight and obese individuals41. In hepatoma cells, Tseng YH et al. demonstrated that 
ANGPTL8 is mainly localized in the cytoplasm with a vesicle-like distribution18, possibly implying that hepato-
cyte lysis linked to steatosis could promote the leakage of ANGPTL8 vesicle in the bloodstream, thus helping to 
explain our findings. Complementing literature data41, 42, our results suggest that ANGPTL8 levels could act as a 
novel surrogate biomarker for liver steatosis in non-PWS obese individuals. As certain adipokines can predict the 
severity of liver steatosis43, however, studies are required to clarify the association between adipocytokines and 
ANGPTL8 levels in steatosis.
In conclusion, ANGPTL8 levels are lower in PWS than obese controls and, overall, they seem to reflect the 
severity of liver steatosis. Further studies should investigate the potential genetic basis of these findings.
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